CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 30 words
    • Secondary endpoints: details revised at 10 of 11 entries
    • Site details revised at 5 of 29 sites
  2. Study completion moved earlier from Sep 2028 to Dec 2026v42
  3. Results first posted: Mar 12, 2026v41
  4. Primary endpoints: 1 to 2
    • Enrollment target: estimated 45 to confirmed 46
    • Secondary endpoints: 7 to 11
    v40
  5. 2 versions Re-verified since Feb 24, 2025, no change to tracked fieldsv38-v39
Show 36 earlier versionsHide 36 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 30 to 29
    • Primary completion date changed from estimate of Jan 2025 to Jan 15, 2025
    v37
  2. Primary completion date: Feb 2027 to Jan 2025v36
  3. Study sites revised (30)v35
  4. Primary completion date: Feb 10, 2027 to Feb 2027
    • Study completion date: Sep 10, 2028 to Sep 2028
    v34
  5. Site details revised at 5 of 30 sitesv33
  6. Site details revised at 12 of 30 sitesv32
  7. Site contacts updated at 2 of 30 sitesv31
  8. Study sites: 29 to 30v30
  9. Study sites: 30 to 29v29
  10. Study sites: 10 to 30v28
  11. 2 versions Re-verified since Oct 11, 2023, no change to tracked fieldsv26-v27
  12. Study sites: 31 to 10v25
  13. Study sites revised (31)v24
  14. Study sites revised (31)v23
  15. Site contacts updated at 1 of 31 sitesv22
  16. Site contacts updated at 1 of 31 sitesv21
  17. Site details revised at 4 of 31 sitesv20
  18. Site details revised at 2 of 31 sitesv19
  19. Site details revised at 3 of 31 sitesv18
  20. Site contacts updated at 3 of 31 sitesv17
  21. Site details revised at 3 of 31 sitesv16
  22. Site contacts updated at 1 of 31 sitesv15
  23. Site details revised at 2 of 31 sitesv14
  24. Study sites revised (31)v13
  25. Re-verified, no change to tracked fieldsv12
  26. Site details revised at 5 of 31 sitesv11
  27. Site details revised at 4 of 31 sitesv10
  28. Site details revised at 5 of 31 sitesv9
  29. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 13, 2023 to Sep 20, 2022
    • Site details revised at 31 of 31 sites
    v8
  30. Re-verified, no change to tracked fieldsv7
  31. Study sites: 30 to 31
    • Eligibility criteria expanded, about 16 words
    v6
  32. Primary completion date: May 1, 2025 to Feb 10, 2027
    • Start date: Aug 15, 2022 to Jan 13, 2023
    • Study sites: 29 to 30
    • Study completion date: Apr 1, 2026 to Sep 10, 2028
    v5
  33. Study sites: 28 to 29v4
  34. Site contacts updated at 1 of 28 sitesv3
  35. Primary completion date: Apr 1, 2025 to May 1, 2025
    • Site contacts updated at 3 of 28 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
365 trials monitored
See 16 trials at risk
Sarcoma
1,029 trials monitored
See 72 trials at risk
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
Trial Details
NCT Number NCT05440786
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Sarcoma, Ewing, Neoplasm Metastasis
Related terms Neoplasm Metastasis, Sarcoma, Ewing
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov